Seagle Brandon-Luke L, Ann Phoebe, Butler Sharlay, Shahabi Shohreh
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Prentice Women's Hospital, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Prentice Women's Hospital, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States.
Gynecol Oncol. 2017 Aug;146(2):285-291. doi: 10.1016/j.ygyno.2017.05.020. Epub 2017 May 19.
To provide prognostic information from a large cohort of women with granulosa cell tumor we analyzed the National Cancer Database.
We performed an observational retrospective cohort analysis of 2680 women with ovarian granulosa cell tumor from the 1998-2013 National Cancer Database. Kaplan-Meier and multivariable Cox proportional-hazards survival analyses were performed for the overall cohort and propensity score matched cohorts to examine the association of surgical staging and adjuvant chemotherapy with survival. A random forest was used to determine important prognostic factors in stages II-IV granulosa cell tumor.
Adjuvant chemotherapy, hormonal therapy, and radiotherapy were not associated with survival. Older age, more comorbidities, prior malignancy, higher stage, poor differentiation, larger tumor size, incomplete surgical staging, and residual disease at a surgical margin were independently associated with increased hazard of death. Among women with stage I disease, each one centimeter increase in tumor size was associated with 4% (2-6%) increased hazard of death (P<0.001). By matched cohort analyses, the hazard ratio (HR) (95% CI) for death associated with incomplete surgical staging was 1.77 (1.30-2.41), P<0.001 among women with stage I disease. Receiving adjuvant chemotherapy was not associated with increased survival among women with stages II-IV disease compared to no adjuvant treatment.
Incomplete surgical staging was associated with increased hazard of death. There was no evidence of increased survival with use of adjuvant chemotherapy. Early and complete surgical resection remains the best evidenced treatment for ovarian granulosa cell tumor.
为了从一大群颗粒细胞瘤女性患者中提供预后信息,我们分析了国家癌症数据库。
我们对1998 - 2013年国家癌症数据库中2680例卵巢颗粒细胞瘤女性患者进行了观察性回顾性队列分析。对整个队列以及倾向评分匹配队列进行了Kaplan - Meier和多变量Cox比例风险生存分析,以检验手术分期和辅助化疗与生存的关联。使用随机森林来确定II - IV期颗粒细胞瘤的重要预后因素。
辅助化疗、激素治疗和放疗与生存无关。年龄较大、合并症较多、既往有恶性肿瘤、分期较高、分化差、肿瘤尺寸较大、手术分期不完全以及手术切缘有残留病灶与死亡风险增加独立相关。在I期疾病的女性中,肿瘤大小每增加1厘米,死亡风险增加4%(2 - 6%)(P < 0.001)。通过匹配队列分析,在I期疾病的女性中,与手术分期不完全相关的死亡风险比(HR)(95%CI)为1.77(1.30 - 2.41),P < 0.001。与未接受辅助治疗相比,接受辅助化疗与II - IV期疾病女性的生存率提高无关。
手术分期不完全与死亡风险增加相关。没有证据表明使用辅助化疗能提高生存率。早期和完整的手术切除仍然是卵巢颗粒细胞瘤最有证据支持的治疗方法。